Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.49 |
| ▸ | ITGAV | P06756 | 5/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6422977 | 1.00 | ITGB3 (0.49) | ITGB3ITGAVITGA2BMEN1KMT2A | |
| SCHEMBL6420205 | 0.90 | ITGB3 (0.50) | ITGB3ITGAVITGA2BPPARDPPARA | |
| SCHEMBL6420201 | 0.90 | ITGB3 (0.50) | ITGB3ITGAVITGA2BPPARDPPARA | |
| SCHEMBL6418698 | 0.87 | ITGB3 (0.53) | ITGB3ITGAVITGA2BPPARDPPARA | |
| SCHEMBL6418693 | 0.87 | ITGB3 (0.53) | ITGB3ITGAVITGA2BPPARDPPARA | |
| SCHEMBL6420654 | 0.86 | ITGB3 (0.44) | ITGB3ITGAVITGA2B | |
| SCHEMBL6420649 | 0.86 | ITGB3 (0.44) | ITGB3ITGAVITGA2B | |
| SCHEMBL6422342 | 0.84 | ITGB3 (0.64) | ITGB3ITGAVITGA2BPPARDOPRK1 | |
| SCHEMBL6418720 | 0.84 | ITGB3 (0.64) | ITGB3ITGAVITGA2BPPARDOPRK1 | |
| SCHEMBL6418726 | 0.84 | ITGB3 (0.64) | ITGB3ITGAVITGA2BPPARDOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0957917-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6825188-B2 | MORE POTENT INHIBITORS OF THE VITRONECTIN RECEPTOR THAN THE FIBRINOGEN | SMITHKLINE BEECHAM CORPORATION | 2004-11-30 | — | — | US | disclosed |
| EP-1017387-A4 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORP (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040082559-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
| US-20030216377-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2003-11-20 | — | — | US | disclosed |
| US-20030125317-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-20030087894-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
| US-20020128257-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| EP-0957917-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-05-15 | — | — | EP | disclosed |
| US-20020040136-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-04-04 | — | — | US | disclosed |
| US-20010014737-A1 | Vitronectin receptor antagonist | HEERDING DIRK (US) | 2001-08-16 | — | — | US | disclosed |
| EP-1017387-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-0957917-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999015170-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998014192-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040136-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | ITGB3 248/4885ITGAV 240/4885ITGA2B 158/4885 |
| US-20030087894-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | ITGB3 248/4885ITGAV 240/4885ITGA2B 158/4885 |
| US-20020128257-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | ITGB3 248/4885ITGAV 240/4885ITGA2B 158/4885 |
| US-20040082559-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | ITGB3 131/4885ITGAV 302/4885ITGA2B 191/4885 |
| US-20030216377-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | ITGB3 248/4885ITGAV 240/4885ITGA2B 158/4885 |
| US-20010014737-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | ITGB3 248/4885ITGAV 240/4885ITGA2B 158/4885 |
| US-20030125317-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | ITGB3 131/4885ITGAV 302/4885ITGA2B 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.